Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World May 19, 2004 Julia Boguslavsky	Is Microfluidics Equipped for HTS? As microfluidics technologies mature and increase in throughput, they are starting to offer a highly accurate, flexible, and economical alternative to conventional high-throughput screening (HTS) platforms.
The Motley Fool April 3, 2007 Brian Lawler	Merck Gets the Combo Merck gets marketing approval for a diabetes combination drug. Investors, take note.
Pharmaceutical Executive March 1, 2013 Ben Comer	Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history.
The Motley Fool January 28, 2011 Luke Timmerman	Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up.
Bio-IT World March 2006 Salamone & Davies	Merck President Touts Technology Benefits Peter Kim, president of Merck Research Laboratories, says that small changes in the drug discovery and development process can yield significant benefits in bringing new drugs to market.
Bio-IT World September 9, 2002 John P. Helfrich	Data Management in High-Throughput Screening The high-throughput drug discovery field requires an optimal IT platform.
BusinessWeek July 30, 2007 Arlene Weintraub	Is Merck's Medicine Working? Spurred by the Vioxx fiasco, CEO Clark is trying to revamp the drug giant's culture. Analysts expect Merck's top line to grow 4%, to $23.5 billion this year, an achievement considering that sales growth had flatlined even before Vioxx imploded.
Pharmaceutical Executive July 1, 2005 Zaborowski, Hammer & Lawler	Informatics Rules How global computer systems helped far-flung research centers at Roche work together
Bio-IT World March 2007 Kevin Davies	Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges.
Fast Company March 15, 2007 Tinker Ready	Not Invented Here The next blockbuster drug could come from anywhere. It's up to Merck's scouts to find it.
The Motley Fool May 27, 2005 Stephen D. Simpson	Once More With Merck Merck has had a busy spring, but are investors any better off?
The Motley Fool January 31, 2006 Stephen D. Simpson	Merck Marking Time There won't be much good news for this pharmaceutical's investors until new products hit the market. If you already own Merck, you probably understand that patience will be the order of the day here.
CIO October 15, 2001 Stephanie Overby	Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...
Bio-IT World May 19, 2004 Malorye Branca	Attack of the Lab-Bots Robots are invading every aspect of discovery and development within pharmaceutical companies, from genotyping to high-throughput screening.
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
Pharmaceutical Executive January 1, 2006 Jeannette Park	Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future.
The Motley Fool July 23, 2007 Brian Lawler	Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition.
Bio-IT World December 15, 2003 Malorye A. Branca	Scenes from a Cell Breakthroughs are making cell-based screening faster, easier, more powerful.
Chemistry World April 14, 2011 Sarah Farley	Fish in chips: growing embryos in microfluidic systems Scientists in the Netherlands and the UK have shown for the first time that an animal embryo can develop in a microfluidic environment.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
Bio-IT World March 2006 Robert M. Frederickson	Integration, Robotics, and Automation The integration of instruments and technology is a key concept driving the development of advanced life-sciences laboratory automation. More sophisticated robotics are also increasingly being integrated into automated systems.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
Bio-IT World November 2006 Kevin Davies	Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights.
Bio-IT World April 16, 2004 Malorye Branca	Finding the Perfect Fit Fragment-based drug discovery is unique and effective.
The Motley Fool February 28, 2007 Brian Lawler	Merck's Mighty Future Merck ups its 2007 financial forecast, while positive developments occur for two of its most promising new therapies.
Chemistry World October 4, 2013 Andy Extance	Amid huge cuts, Merck vows research focus US-based drug giant Merck & Co will cut 8,500 more jobs as it seeks to cut costs by $2.5 billion
The Motley Fool February 13, 2009 Brian Orelli	The Easy Way to Develop Drugs Merck buys a pipeline of follow-on biologics and a building to produce them.
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Chemistry World November 2009 Derek Lowe	Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
BusinessWeek March 6, 2006 Amy Barrett	Merck: Out Of The Ivory Tower Merck's pragmatic strategy includes tweaking the vitamin niacin to make it a blockbuster.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
The Motley Fool June 30, 2009 Brian Orelli	A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention.
The Motley Fool April 17, 2007 Brian Lawler	Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance.
PC Magazine October 10, 2007 John Brandon	Computing a Cure Scientists are building digital libraries of drug data to fight potential outbreaks.
Chemistry World May 2010 Derek Lowe	Column: In the pipeline The author wonders whether tagging molecules with fluorescent labels for assay is like tracking the members of a shoal of fish by tying each one to a whale. In the pharmaceutical business, our work absolutely lives and dies by assay results.
Chemistry World January 2010 Derek Lowe	Column: In the pipeline I've recently marked my 20th year of drug discovery research, which prompted me to think about what has changed since I started work in the industry.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool July 21, 2005 Stephen D. Simpson	Merck Is No Quack Weighing the pros and cons, it appears that Merck's stock is trading pretty much where it should be. What does make the story a bit more interesting is that robust dividend, which is currently yielding almost 4.8%.
The Motley Fool December 29, 2006 Brian Lawler	Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
The Motley Fool April 30, 2011 Brian Orelli	No Long-Term Guidance? No Problem! Looking good, Merck.
Chemistry World June 2009 Derek Lowe	Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool December 1, 2009 Robert Steyer	Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones.
The Motley Fool September 28, 2009 Brian Orelli	Here We Go Again With Possible Side Effects The FDA says it has received 88 reports of pancreatitis in patients taking Merck's Januvia and Janumet.